Header ENETS-NANETS-Webinar
Webinar

NANETS - ENETS webinar: Virtual NET tumour board
Precision therapies and emerging strategies in NEN management

This webinar is part of ENETS’ ongoing educational collaboration with the North American Neuroendocrine Tumor Society (NANETS), supporting international dialogue and shared learning in NET care.

Continuing the success of the annual NANETS–ENETS collaborative series, the 2025 Virtual NET Tumor Board will bring together multidisciplinary experts from both societies to explore emerging precision therapy strategies in neuroendocrine neoplasms (NENs) through interactive case-based learning.

This year’s discussion will highlight advances in immunotherapy, biomarkers, and theranostic approaches, focusing on how these evolving modalities are integrated into patient management. Two real-world cases, one from each society, will be presented to illustrate clinical decision-making, sequencing of therapies, and the multidisciplinary coordination required to optimise outcomes.

This webinar is free and open to all healthcare professionals. Prior registration is required to attend. The Zoom registration link is now available—click the button below to register and secure your place.

 

Educational Level:

Basic

Keywords:

multidisciplinary management, re-biopsy, clinical trial, carcinoid syndrome

Downloads:

Agenda:

Moderators: Aman CHAUHAN, USA and Mairéad McNAMARA, GBR

12:00 - 12:05 EDT / 18:00 - 18:05 CET       Opening comments – Aman CHAUHAN, USA

12:05 - 12:15 EDT / 18:05 - 18:15 CET       Case presentation: Advanced grade 2 pancreatic neuroendocrine tumour (PanNET) – Aman CHAUHAN, USA

12:15 - 12:45 EDT / 18:15 - 18:45 CET       Panel discussion

Panellists:

  • Medical Oncology: Aman CHAUHAN, USA & Suayib YALCIN, TUR
  • Surgical Oncology: Maria DANIELI, ITA & Aaron SASSON, USA
  • Nuclear Medicine: Tessa BRABANDER, NED & Beth CHASEN, USA
  • Interventional Radiology: Timm DENECKE, GER & Nicholas FIDELMAN, USA

12:45 - 12:55 EDT / 18:45 - 18:55 CET       Case presentation: Grade 2 small bowel or ileum NET (advanced/metastatic) – Suayib YALCIN, TUR

12:55 - 13:25 EDT / 18:55 - 19:25 CET       Panel discussion (with moderators and panellists listed above)

13:25 - 13:30 EDT / 19:25 - 19:30 CET       Closing comments – Mairéad McNAMARA, GBR

 

Moderators:

Aman CHAUHAN
Aman CHAUHAN
Mairéad McNAMARA
Mairéad McNAMARA

Speakers:

Tessa BRABANDER
Tessa BRABANDER
Beth CHASEN
Beth CHASEN
Maria DANIELI
Maria DANIELI
Timm DENECKE
Timm DENECKE
Nicholas FIDELMAN
Nicholas FIDELMAN
Suayib YALCIN
Suayib YALCIN
Aaron SASSON
Aaron SASSON

The webinar series is intended for HCPs qualified by law to prescribe medicine.

 
 

Conflict of Interest Disclosure

In line with EACCME® standards, all faculty participating in this webinar have disclosed any potential conflicts of interest. The disclosures are available to all participants before and during the webinar session.

  • Mairéad McNAMARA (moderator) reports the following potential conflicts of interest:
    • Receipt of grants/research supports: Ipsen, Astra Zeneca, Servier, NuCana
    • Participation in a company sponsored speaker’s bureau: Astra Zeneca, AAA (Novartis)
  • Aman CHAUHAN (moderator) reports the following potential conflicts of interest:
    • Receipt of grants/research supports: Seneca Therapeutics, BMS, Clovis, EMD Serono, Nanopharmaceutics
    • Receipt of honoraria or consultation fees: Novartis, Crinetics, Curium, Lantheus, Exelixis, Ipsen, Tersera, Lexicon, Sanofi, Seneca Therapeutics, BI, ITM
  • Suayib YALCIN (speaker) has no conflicts of interests to declare
  • Maria DANIELI (speaker) has no conflicts of interests to declare
  • Aaron SASSON (speaker) reports the following potential conflicts of interest:
    • Stock shareholder: Part owner, Sanguine Diagnostics and Therapeutics
  • Tessa BRABANDER (speaker) reports the following potential conflicts of interest:
    • Receipt of grants/research supports: Novartis (all paid to the institute)
    • Receipt of honoraria or consultation fees: Novartis (all paid to the institute)
  • Beth CHASEN (speaker) reports the following potential conflicts of interest:
    • Receipt of honoraria or consultation fees: Lantheus
  • Timm DENECKE (speaker) reports the following potential conflicts of interest:
    • Receipt of grants/research supports: Bayer, Guerbet
    • Receipt of honoraria or consultation fees: Bayer, Perceptive, IPSEN, Novartis, AstraZeneca, Takeda, MSD, Roche, be imaging, Siemens, AAA
  • Nicholas FIDELMAN (speaker) reports the following potential conflicts of interest:
    • Receipt of grants/research supports: MERCK, Inc.

       

 
Back to webinar archive